
Kite Pharma names Paul Jenkinson CFO
pharmafile | May 23, 2016 | Appointment | Research and Development, Sales and Marketing |Â Â appointment, cfo, kite pharmaÂ
Kite Pharma (Nasdaq: KITE) has appointed Paul Jenkinson its chief financial officer.
Jenkinson succeeds Cynthia Butitta, who will continue in her role as Kite’s chief operating officer.
Jenkinson will report to Arie Belldegrun, the chief executive of the company. Most recently he was vice president of global commercial and corporate finance for Allergan (NYSE: AGN).
Belldegrun said: “Paul brings extensive experience in international financial management and operations to Kite as we prepare for the potential launch of our lead candidate KTE-C19 next year.”
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

EMA’s CHMP recommends conditional approval for Kite Pharma’s CAR T therapy for mantle cell lymphoma
Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy known as KTE-X19 has received …

Kite secures FDA approval for second CAR T therapy Tecartus in relapsed or refractory mantle cell lymphoma
Kite Pharma has chalked up another regulatory success for its parent company Gilead with the …






